Immunotherapy After a Kidney, Liver or Heart Transplant — The Rejection Risk

Sometimes, but this is one of the highest-risk situations in immunotherapy. Checkpoint inhibitors can trigger rejection of a transplanted kidney, liver or heart. It is not an absolute no, and it is never a decision the cancer team makes alone — your transplant unit has to be part of it.

The reason is mechanical rather than mysterious. Anti-rejection medicines exist to hold your immune system back so it does not attack the transplanted organ. Checkpoint inhibitors exist to take a brake off that same immune system so it can attack cancer. The two aims point in opposite directions, in the same body, at the same time.

That makes this a genuinely different conversation from other immune conditions. Living with an autoimmune condition such as psoriasis is usually a caution — something to monitor closely rather than a barrier. A transplanted organ is a different order of risk, because what is at stake is not a flare that settles but an organ you may not get back. Even so, “different order of risk” is not the same as “impossible”, and being told no in one sentence, without an assessment, is not an answer.

This page is general patient education. It cannot tell you whether immunotherapy is safe for you. That assessment needs your cancer stage, your graft function, your transplant history and your current medicines in front of a medical oncologist working with the unit that follows your transplant.

Substantial, and higher than for any other pre-existing immune condition. Published case series and reviews report allograft rejection in a large minority of solid-organ transplant recipients given checkpoint inhibitors. Rejection usually appears early, often within the first few weeks of the first dose. No series is large enough to give you a reliable personal number.

Two things are worth separating. The first is rejection of the graft — the immune system turning on the transplanted organ. The second is the ordinary immune-related side effects that any patient on immunotherapy can develop, in the thyroid, bowel, liver, lung or skin. A transplant raises the first risk sharply. It does not protect you from the second.

The evidence itself is the honest limitation. Transplant recipients were excluded from the trials that got these treatments approved, so what exists is case reports, published series and registry data collected afterwards. Immunotherapy toxicity guidance from ASCO, ESMO and NCCN reflects that gap: for solid-organ transplant recipients it points to individual, multidisciplinary assessment rather than a fixed rule, because there is no randomised evidence in this group to base one on. Those sources agree that the risk is real and that rejection tends to come early. They disagree on almost everything else, including how much difference the anti-rejection regimen makes. Anyone quoting you a confident single percentage for your situation is ahead of the data.

Rejection is also not always reversible. In some reported cases treatment was stopped, immunosuppression was increased and the graft recovered. In others the organ was lost. That uncertainty is precisely why the decision is made in advance and in writing, rather than worked out after something goes wrong.

General patterns from published case series and registries only — the same limited evidence base that ASCO, ESMO and NCCN guidance describes — not risk figures for your case. Your own teams’ assessment overrides anything in this table, in either direction. Other factors weigh heavily too: how long ago the transplant was, whether you have had rejection episodes before, how well the graft is working now, and how much immunosuppression you currently need.

Yes, in selected patients. It is usually considered when the cancer is life-threatening, when other treatments have been used or are not options, and when you have understood and accepted that the graft may be lost. It is done inside a documented joint plan, with the transplant unit watching the organ from the first dose.

Several things make it more likely to be considered. A kidney graft rather than a liver or heart graft, because dialysis exists as a fallback. A transplant done many years ago with stable function since. No history of rejection episodes. A cancer where immunotherapy is one of the few remaining treatments that could change the situation. And, above all, a patient who has been told the trade-off in plain words and has made the choice themselves.

Several things push the other way. A recent transplant. A graft that is already working poorly. Previous rejection episodes. A heart or liver graft where losing the organ would not be survivable. Or a cancer where equally reasonable treatments exist that carry no rejection risk at all — in which case the sensible answer is to use those first, and that is not a refusal, it is sequencing.

What is not acceptable is a no with no reasoning attached. A properly made decision names your organ, your graft function, your medicines and the alternative plan. If you were told immunotherapy is impossible without any of that being examined, a second opinion from a medical oncologist is reasonable — not to find someone who will say yes, but to find out whether the question was ever properly asked. Sometimes a second opinion confirms the first answer, and knowing that with confidence is worth having too. Who Should Not Have Immunotherapy at All? sets out the genuine contraindications without softening them.

• Local treatment first, where it can be definitive — surgery, radiotherapy, ablation or other local approaches. For several cancers that appear after transplant, including skin cancers, local treatment is the main plan and no systemic immune treatment is needed.
• Chemotherapy — works differently and does not carry a graft-rejection risk. It has its own side effects and needs care in patients with reduced kidney or liver function, which the transplant team helps plan.
• Targeted therapy, where a suitable biomarker is found — if testing identifies a target, this can be an effective option that leaves the immune brake in place.
• Hormone therapy, for the cancers it applies to — no rejection risk, and often well tolerated alongside anti-rejection medicines.
• Adjusting immunosuppression as part of the cancer plan — for some cancers that develop after transplant, changing the anti-rejection regimen is itself a recognised step. A transplant-team decision, never an oncology-only one.
• A clinical trial, or supportive care alone — both are legitimate. Trials are informational here: taking part is never promised and enrolment depends on the trial’s own criteria.

If your team recommends one of these instead of immunotherapy, ask them to say why in those terms — that it is a better fit or a safer sequence, rather than simply that immunotherapy is “not allowed”. The reasoning is what tells you the decision was actually made.

• Which organ, and the year — time since transplant is one of the factors that carries most weight.
• Your current anti-rejection medicines with doses — the doses matter as much as the names.
• Your most recent graft function results — kidney or liver blood tests, or your latest cardiology assessment.
• Any history of rejection episodes — when, how severe, and what settled them. Two lines is enough.
• Your transplant unit’s contact details — so the two teams speak to each other directly instead of relaying messages through you.
• Your cancer reports — biopsy report, staging scans and any biomarker testing already done.

• If the immediate question is your anti-rejection or immune-suppressing medicines, Taking Immunosuppressant Medicines and Starting Immunotherapy explains how baseline immunosuppression is assessed.
• If you have already been turned down without a reason you understand, Second Opinion When You Have Been Refused Immunotherapy sets out what to ask for.
• If your immune condition is autoimmune rather than a transplant, Immunotherapy With Psoriasis and Immunotherapy With an Autoimmune Disease cover the far more common caution.
• For how immunotherapy is delivered, monitored and followed up as day care, see Immunotherapy at CION Cancer Clinics.

General patient-education information only. Nothing here states or implies that immunotherapy is safe, suitable or unsuitable for you — that assessment is made by your treating medical oncologist together with the unit that follows your transplant. Immunotherapy is administered as day care at CION centres; CION does not run a transplant programme and does not provide CAR-T or other cell therapies. Response-assessment PET-CT is coordinated at partner imaging centres.

Get the Transplant Question Assessed Properly

A medical oncologist, working with the unit that follows your transplant, can set out what immunotherapy would risk in your case — and what the alternatives to it are.

This page is general patient-education information, not a substitute for the written assessment your own oncology team and transplant unit give you for your specific case.